Skip to main content

Table 1 Patients’ baseline characteristics (N = 20)

From: Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants including edoxaban

Age 66 ± 10.5 years
Female sex 8 (40%)
Edoxaban dose 60 mg daily: 15 (75%)
30 mg daily: 5 (25%)
Body weight 80.5 ± 20.1 kg
Body Mass Index (BMI) 27.0 ± 5.9 kg/m2
Glomerular filtration rate (Cockcroft-Gault) 83 ± 26 mL/min/1.73m2
Risk factors
 Arterial hypertension 16 (80%)
 Hyperlipidemia 7 (35%)
 Diabetes mellitus 1 (5%)
 History of stroke 20 (100%)
 Congestive heart failure 2 (10%)
 Coronary heart disease 7 (35%)
 History of myocardial infarction 5 (25%)
 Smoking 4 (20%)
Indication for edoxaban therapy
 Atrial fibrillation 12 (60%)
 Stroke associated with patent foramen ovale 6 (30%)
 Embolic stroke of undetermined source 2 (10%)
Concomitant antiplatelet therapy 4 (20%)
  1. Continuous variables are displayed as mean ± standard deviation. Nominal variables are displayed as absolute quantity (percentage)